Amnioinfusion for reducing umbilical artery lactate among fetuses at risk of neurologic injury: a pilot randomized clinical trial.
Brock E Polnaszek, Julia Rossen, Matthew Scarpaci...
https://pubmed.ncbi.nlm.nih.gov/39117278/Actively Recruiting
Led by Medical College of Wisconsin · Updated on 2026-10-26
80
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying whether a treatment called amnioinfusion during labor can help protect the brains of newborns whose mothers have an infection called chorioamnionitis. This condition can cause inflammation and fever in the mother, which may stress the baby and lead to brain injury. The study is designed to test if amnioinfusion can reduce early brain injury markers measured at birth. Participants will be randomly assigned to receive either standard labor care or amnioinfusion using room-temperature lactated Ringers solution. The amnioinfusion involves a 500 mL fluid bolus over 30 minutes through an intrauterine pressure catheter, followed by a continuous infusion until delivery or a total of 1L. Both groups will continue receiving standard infection treatments during labor. Throughout the study, researchers will collect umbilical cord blood at delivery to test for brain injury biomarkers like S100B and others. Additional outcomes measured include neonatal and maternal health, developmental screening up to one year after birth, and healthcare use for mothers and children. The study lasts from labor through one year postpartum, tracking safety and developmental results.
CONDITIONS
Amnioinfusion for Chorioamnionitis: Targeting Neonatal Brain Injury Biomarkers
B
Brock E Polnaszek, MD,MPH
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Medical College of Wisconsin
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Amnioinfusion (Experimental Arm) | Standard Care (Comparator Arm) |
|---|---|---|
| What is it? | A procedure where room temperature lactated ringer's solution is infused into the uterus during labor using an intrauterine pressure catheter, in patients with chorioamnionitis. | Routine obstetric management as decided by the delivery provider, without additional amnioinfusion. |
| Role in the trial | Investigation of whether a single bolus and maintenance amnioinfusion reduces markers of neonatal brain injury among babies born to mothers with chorioamnionitis. | Serves as the comparator arm receiving the usual care without amnioinfusion to evaluate differences in neonatal outcomes. |
| Primary use | To assess whether amnioinfusion reduces neonatal brain injury biomarkers and improves immediate and longer-term neonatal outcomes in cases of chorioamnionitis during labor. | Provides the benchmark for obstetric and neonatal outcomes using routine care, against which the effects of amnioinfusion are evaluated. |
| How is it given or performed? | A 500 mL bolus of room temperature lactated ringer's is infused over 30 minutes through an intrauterine pressure catheter, with a maintenance infusion of 125 mL/hour until 1 L is delivered or until delivery. | Participants receive routine care as determined by their provider, without amnioinfusion. |
| Evidence status | Currently under study; no published results from this trial yet. A recent pilot randomized trial found that amnioinfusion may reduce umbilical artery lactate in similar populations. | Standard care is the established approach and provides the reference for all outcome comparisons in this setting. |
| Important limitations | Effects on long-term neonatal brain development remain uncertain. Larger studies are needed to confirm reduction in neurologic injury biomarkers and to evaluate rare adverse outcomes. | Standard care may not address all risks of neurological complications associated with chorioamnionitis and is not an active intervention targeting neonatal brain injury biomarkers. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Until delivery or until 1 liter of fluid is infused
Participants will receive either amnioinfusion with room-temperature fluid during labor or standard care without amnioinfusion, alongside usual infection treatments.
Continuous infusion during labor
Duration - Up to 1 year after delivery
Researchers will monitor newborn brain injury markers and developmental progress up to one year after birth. Maternal and infant health outcomes will also be tracked.
Periodic assessments and developmental screenings
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Brock E Polnaszek, Julia Rossen, Matthew Scarpaci...
https://pubmed.ncbi.nlm.nih.gov/39117278/Medical College of Wisconsin
Lead Sponsor